Bryn Pharma Appoints Pharmaceutical Industry Veteran Anne Clem Whitaker to Its Board of Directors
“Anne is an accomplished pharmaceutical executive who brings strong cross-functional operational and commercialization expertise to Bryn. She has a demonstrated track record of building successful businesses and leading teams through transformational change to drive business growth. We look forward to her contributions as we work toward the goal of bringing our innovative anaphylaxis treatment to market,” said
“Bryn has made tremendous strides in researching and developing a new approach to treating life-threatening allergic reactions. I’m excited to collaborate with the company’s leadership to chart a course in bringing their investigational technology to market,” said
About Bryn Pharma
Bryn Pharma is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with
Forward Looking Statements
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company’s products to patients, market and physician acceptance of the Company’s products, intellectual property protection and competitive product offerings, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. An investment in the Company’s securities entails significant risks and is suitable only for sophisticated investors who can afford a loss of their entire investment; no assurance can be given that investment objectives will be achieved. In considering the performance information contained herein, you should bear in mind that past performance is not necessarily indicative of future results; there can be no assurance that the Company will achieve comparable results or that any projected returns will be met. The Company does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005123/en/
Ph: 704-341-1544
Rebecca [at] RNTCommunications.com
Source: